Reuters logo
BRIEF-Medivir licenses exclusive rights to MIV-802 for greater China to Ascletis
August 18, 2017 / 6:11 AM / a month ago

BRIEF-Medivir licenses exclusive rights to MIV-802 for greater China to Ascletis

Aug 18 (Reuters) - Medivir

* Medivir licenses exclusive rights to MIV-802 for greater China to Ascletis

* Under the terms of the agreement, Medivir received an upfront payment, and is entitled to receive milestones based on successful development through commercial launch and tiered royalties on net sales of MIV-802 containing products Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below